# Bruker Corp: financial statements, quarterly BRKR · Nasdaq · CIK 1109354 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/brkr.md) · [Financials](/companies/brkr/financials.md) · [Filings](/companies/brkr/filings.md) · [Insiders](/companies/brkr/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/brkr/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [743](/filings/0000950170-24-123298.md) | [855 d](/filings/0001193125-26-082523.md) | [722](/filings/0000950170-25-065610.md) | [801](/filings/0000950170-25-103333.md) | [864](/filings/0001193125-25-267049.md) | [980 d](/filings/0001193125-26-082523.md) | [801](/filings/0001193125-26-211889.md) | [797](/filings/0001193125-26-335226.md) | [861](/filings/0001193125-25-267049.md) | [977 d](/filings/0001193125-26-082523.md) | [823](/filings/0001193125-26-211889.md) | [839](/filings/0001193125-26-335226.md) | | Cost of revenue | $m | [360](/filings/0000950170-24-123298.md) | [424 d](/filings/0001193125-26-082523.md) | [369](/filings/0000950170-25-065610.md) | [416](/filings/0000950170-25-103333.md) | [446](/filings/0001193125-25-267049.md) | [486 d](/filings/0001193125-26-082523.md) | [410](/filings/0001193125-26-211889.md) | [440](/filings/0001193125-26-335226.md) | [481](/filings/0001193125-25-267049.md) | [528 d](/filings/0001193125-26-082523.md) | [444](/filings/0001193125-26-211889.md) | [423](/filings/0001193125-26-335226.md) | | Gross profit | $m | [383](/filings/0000950170-24-123298.md) | [430 d](/filings/0001193125-26-082523.md) | [353](/filings/0000950170-25-065610.md) | [385](/filings/0000950170-25-103333.md) | [419](/filings/0001193125-25-267049.md) | [493 d](/filings/0001193125-26-082523.md) | [391](/filings/0001193125-26-211889.md) | [358](/filings/0001193125-26-335226.md) | [379](/filings/0001193125-25-267049.md) | [449 d](/filings/0001193125-26-082523.md) | [380](/filings/0001193125-26-211889.md) | [416](/filings/0001193125-26-335226.md) | | Research and development | $m | [71.3](/filings/0000950170-24-123298.md) | [83.5 d](/filings/0001193125-26-082523.md) | [81.8](/filings/0000950170-25-065610.md) | [92.2](/filings/0000950170-25-103333.md) | [98.1](/filings/0001193125-25-267049.md) | [104 d](/filings/0001193125-26-082523.md) | [97.1](/filings/0001193125-26-211889.md) | [100](/filings/0001193125-26-335226.md) | [98.3](/filings/0001193125-25-267049.md) | [99.6 d](/filings/0001193125-26-082523.md) | [101](/filings/0001193125-26-211889.md) | [94.3](/filings/0001193125-26-335226.md) | | Selling, general and administrative | $m | [178](/filings/0000950170-24-123298.md) | [211 d](/filings/0001193125-26-082523.md) | [195](/filings/0000950170-25-065610.md) | [221](/filings/0000950170-25-103333.md) | [230](/filings/0001193125-25-267049.md) | [247 d](/filings/0001193125-26-082523.md) | [225](/filings/0001193125-26-211889.md) | [231](/filings/0001193125-26-335226.md) | [243](/filings/0001193125-25-267049.md) | [247 d](/filings/0001193125-26-082523.md) | [242](/filings/0001193125-26-211889.md) | [239](/filings/0001193125-26-335226.md) | | Operating income | $m | [125](/filings/0000950170-24-123298.md) | [104 d](/filings/0001193125-26-082523.md) | [64.8](/filings/0000950170-25-065610.md) | [48.1](/filings/0000950170-25-103333.md) | [68.1](/filings/0001193125-25-267049.md) | [72.1 d](/filings/0001193125-26-082523.md) | [31.8](/filings/0001193125-26-211889.md) | [11.9](/filings/0001193125-26-335226.md) | [(51.8)](/filings/0001193125-25-267049.md) | [76.3 d](/filings/0001193125-26-082523.md) | [10.2](/filings/0001193125-26-211889.md) | [(65.3)](/filings/0001193125-26-335226.md) | | Interest expense | $m | [3.9](/filings/0000950170-23-062192.md) | [4.4 d](/filings/0000950170-24-023038.md) | [5.0](/filings/0000950170-24-057736.md) | [15.7](/filings/0000950170-24-094832.md) | [11.6](/filings/0001193125-25-267049.md) | [15.6 d](/filings/0001193125-26-082523.md) | [13.1](/filings/0001193125-26-211889.md) | [15.7](/filings/0001193125-26-335226.md) | [20.3](/filings/0001193125-25-267049.md) | [11.2 d](/filings/0001193125-26-082523.md) | [12.2](/filings/0001193125-26-211889.md) | [17.8](/filings/0001193125-26-335226.md) | | Income tax | $m | [30.8](/filings/0000950170-24-123298.md) | [37.1 d](/filings/0001193125-26-082523.md) | [19.8](/filings/0000950170-25-065610.md) | [16.1](/filings/0000950170-25-103333.md) | [14.8](/filings/0001193125-25-267049.md) | [40.7 d](/filings/0001193125-26-082523.md) | [8.7](/filings/0001193125-26-211889.md) | [(3.1)](/filings/0001193125-26-335226.md) | [(14.1)](/filings/0001193125-25-267049.md) | [37.8 d](/filings/0001193125-26-082523.md) | [2.5](/filings/0001193125-26-211889.md) | [14.2](/filings/0001193125-26-335226.md) | | Net income | $m | [88.1](/filings/0000950170-24-123298.md) | [206 d](/filings/0001193125-26-082523.md) | [50.9](/filings/0000950170-25-065610.md) | [7.6](/filings/0000950170-25-103333.md) | [40.9](/filings/0001193125-25-267049.md) | [13.7 d](/filings/0001193125-26-082523.md) | [17.4](/filings/0001193125-26-211889.md) | [7.6](/filings/0001193125-26-335226.md) | [(59.6)](/filings/0001193125-25-267049.md) | [26.0 d](/filings/0001193125-26-082523.md) | [14.4](/filings/0001193125-26-211889.md) | [(52.0)](/filings/0001193125-26-335226.md) | | Diluted EPS | $ per share | [0.60](/filings/0000950170-24-123298.md) | not reported | [0.35](/filings/0000950170-25-065610.md) | [0.05](/filings/0000950170-25-103333.md) | [0.27](/filings/0001193125-25-267049.md) | not reported | [0.11](/filings/0001193125-26-211889.md) | [0.05](/filings/0001193125-26-335226.md) | [(0.41)](/filings/0001193125-25-267049.md) | not reported | [0.02](/filings/0001193125-26-211889.md) | [(0.41)](/filings/0001193125-26-335226.md) | | Basic EPS | $ per share | [0.60](/filings/0000950170-24-123298.md) | not reported | [0.35](/filings/0000950170-25-065610.md) | [0.05](/filings/0000950170-25-103333.md) | [0.27](/filings/0001193125-25-267049.md) | not reported | [0.11](/filings/0001193125-26-211889.md) | [0.05](/filings/0001193125-26-335226.md) | [(0.41)](/filings/0001193125-25-267049.md) | not reported | [0.02](/filings/0001193125-26-211889.md) | [(0.41)](/filings/0001193125-26-335226.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfRevenue - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [364](/filings/0000950170-23-062192.md) | [488](/filings/0000950170-25-030897.md) | [340](/filings/0000950170-24-057736.md) | [170](/filings/0000950170-24-094832.md) | [148](/filings/0000950170-24-123298.md) | [183](/filings/0001193125-26-082523.md) | [184](/filings/0000950170-25-065610.md) | [92.0](/filings/0000950170-25-103333.md) | [293](/filings/0001193125-25-267049.md) | [299](/filings/0001193125-26-335226.md) | [133](/filings/0001193125-26-211889.md) | [185](/filings/0001193125-26-335226.md) | | Current assets | $m | [2,029](/filings/0000950170-23-062192.md) | [2,164](/filings/0000950170-25-030897.md) | [2,140](/filings/0000950170-24-057736.md) | [2,153](/filings/0000950170-24-094832.md) | [2,191](/filings/0000950170-24-123298.md) | [2,053](/filings/0001193125-26-082523.md) | [2,112](/filings/0000950170-25-065610.md) | [2,163](/filings/0000950170-25-103333.md) | [2,351](/filings/0001193125-25-267049.md) | [2,213](/filings/0001193125-26-335226.md) | [2,104](/filings/0001193125-26-211889.md) | [2,225](/filings/0001193125-26-335226.md) | | Total assets | $m | [3,820](/filings/0000950170-23-062192.md) | [4,250](/filings/0000950170-25-030897.md) | [4,506](/filings/0000950170-24-057736.md) | [5,903](/filings/0000950170-24-094832.md) | [6,113](/filings/0000950170-24-123298.md) | [5,807](/filings/0001193125-26-082523.md) | [5,933](/filings/0000950170-25-065610.md) | [6,340](/filings/0000950170-25-103333.md) | [6,435](/filings/0001193125-25-267049.md) | [6,241](/filings/0001193125-26-335226.md) | [6,131](/filings/0001193125-26-211889.md) | [6,053](/filings/0001193125-26-335226.md) | | Current liabilities | $m | [1,072](/filings/0000950170-23-062192.md) | [1,202](/filings/0000950170-25-030897.md) | [1,183](/filings/0000950170-24-057736.md) | [1,305](/filings/0000950170-24-094832.md) | [1,322](/filings/0000950170-24-123298.md) | [1,281](/filings/0001193125-26-082523.md) | [1,345](/filings/0000950170-25-065610.md) | [1,347](/filings/0000950170-25-103333.md) | [1,268](/filings/0001193125-25-267049.md) | [1,279](/filings/0001193125-26-335226.md) | [1,355](/filings/0001193125-26-211889.md) | [1,205](/filings/0001193125-26-335226.md) | | Total liabilities | $m | not reported | [2,837](/filings/0000950170-25-030897.md) | [3,056](/filings/0000950170-24-057736.md) | [4,078](/filings/0000950170-24-094832.md) | [4,270](/filings/0000950170-24-123298.md) | [3,992](/filings/0001193125-26-082523.md) | not reported | not reported | not reported | [3,731](/filings/0001193125-26-082523.md) | not reported | not reported | | Long-term debt | $m | [1,099](/filings/0000950170-23-062192.md) | [1,160](/filings/0000950170-25-030897.md) | [1,357](/filings/0000950170-24-057736.md) | [2,132](/filings/0000950170-24-094832.md) | [2,265](/filings/0000950170-24-123298.md) | [2,062](/filings/0001193125-26-082523.md) | [2,076](/filings/0000950170-25-065610.md) | [2,380](/filings/0000950170-25-103333.md) | [1,984](/filings/0001193125-25-267049.md) | [1,853](/filings/0001193125-26-335226.md) | [1,663](/filings/0001193125-26-211889.md) | [1,815](/filings/0001193125-26-335226.md) | | Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $m | [1,209](/filings/0000950170-23-062192.md) | [1,377](/filings/0000950170-25-030897.md) | [1,415](/filings/0000950170-24-057736.md) | [1,789](/filings/0000950170-24-094832.md) | [1,807](/filings/0000950170-24-123298.md) | [1,781](/filings/0001193125-26-082523.md) | [1,833](/filings/0001193125-26-335226.md) | [1,819](/filings/0001193125-26-335226.md) | [2,432](/filings/0001193125-25-267049.md) | [2,457](/filings/0001193125-26-082523.md) | [2,467](/filings/0001193125-26-335226.md) | [2,400](/filings/0001193125-26-335226.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Short-term borrowings: not reported - Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [44.1 d](/filings/0000950170-24-123298.md) | [206 d](/filings/0001193125-26-082523.md) | [21.8](/filings/0000950170-25-065610.md) | [1.1 d](/filings/0000950170-25-103333.md) | [38.4 d](/filings/0001193125-25-267049.md) | [190 d](/filings/0001193125-26-082523.md) | [65.0](/filings/0001193125-26-211889.md) | [(128) d](/filings/0001193125-26-335226.md) | [(33.2) d](/filings/0001193125-25-267049.md) | [230 d](/filings/0001193125-26-082523.md) | [71.2](/filings/0001193125-26-211889.md) | [(77.4) d](/filings/0001193125-26-335226.md) | | Capital expenditure | $m | [26.9 d](/filings/0000950170-24-123298.md) | [31.5 d](/filings/0001193125-26-082523.md) | [21.4](/filings/0000950170-25-065610.md) | [24.6 d](/filings/0000950170-25-103333.md) | [32.6 d](/filings/0001193125-25-267049.md) | [36.7 d](/filings/0001193125-26-082523.md) | [26.0](/filings/0001193125-26-211889.md) | [21.3 d](/filings/0001193125-26-335226.md) | [20.9 d](/filings/0001193125-25-267049.md) | [22.6 d](/filings/0001193125-26-082523.md) | [24.2](/filings/0001193125-26-211889.md) | [28.8 d](/filings/0001193125-26-335226.md) | | Dividends paid | $m | [7.4 d](/filings/0000950170-24-123298.md) | [7.3 d](/filings/0001193125-26-082523.md) | [7.3](/filings/0000950170-25-065610.md) | [7.7 d](/filings/0000950170-25-103333.md) | [7.6 d](/filings/0001193125-25-267049.md) | [7.6 d](/filings/0001193125-26-082523.md) | [7.7](/filings/0001193125-26-211889.md) | [7.6 d](/filings/0001193125-26-335226.md) | [0.0 d](/filings/0001193125-25-267049.md) | [7.5 d](/filings/0001193125-26-082523.md) | [7.6](/filings/0001193125-26-211889.md) | [7.5 d](/filings/0001193125-26-335226.md) | | Share repurchases | $m | [79.5 d](/filings/0000950170-24-123298.md) | [50.4 d](/filings/0001193125-26-082523.md) | [0.0](/filings/0000950170-25-065610.md) | [0.0 d](/filings/0000950170-25-103333.md) | [0.0 d](/filings/0001193125-25-267049.md) | [0.0 d](/filings/0001193125-26-082523.md) | [10.0](/filings/0001193125-26-211889.md) | [0.0 d](/filings/0000950170-25-103333.md) | [0.0 d](/filings/0001193125-25-267049.md) | [0.0 d](/filings/0001193125-26-082523.md) | [0.0](/filings/0001193125-26-211889.md) | not reported | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Dividends paid: us-gaap:PaymentsOfDividendsCommonStock - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [0.0](/filings/0000950170-23-062192.md) | [0.0](/filings/0000950170-24-057736.md) | [0.0](/filings/0000950170-24-094832.md) | [0.0](/filings/0000950170-24-123298.md) | [0.0](/filings/0000950170-25-065610.md) | [148](/filings/0000950170-25-103333.md) | [152](/filings/0001193125-25-267049.md) | [152](/filings/0001193125-26-211889.md) | [152](/filings/0001193125-26-335226.md) | [152](/filings/0001193125-25-267049.md) | [153](/filings/0001193125-26-211889.md) | [152](/filings/0001193125-26-335226.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 151,719,365 at 2025-07-29, from the cover of the [10-Q filed 2025-08-06](/filings/0000950170-25-103333.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.